Drug intelligence / Profile preview

E7046 + atezolizumab

Development stage: Unknown
Lead developer: Eisai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

E7046 + atezolizumab is an investigational combination of two drugs for cancer immunotherapy. **E7046 (also known as AN0025)** is a highly selective small-molecule antagonist of the E-type prostanoid receptor 4 (EP4), targeted to reverse prostaglandin E2-mediated immunosuppression in the tumor microenvironment[1][4]. **Atezolizumab** is a monoclonal antibody that blocks programmed death-ligand 1 (**PD-L1**), enhancing T-cell mediated antitumor immune responses[4]. The combination is being investigated for synergistic immunomodulation by concurrently blocking distinct suppressive pathways in tumors.

Brand names: Tecentriq
Other names: AN0025AN-0025AN 0025E7046E-7046E 7046atezolizumab

Targets

CD274 (Programmed cell death protein 1 ligand 1)PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on E7046 + atezolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E7046 + atezolizumab.

Explore the full profile